MedTrace Logo

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 770

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus).

This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison.

Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.

Conditions

  • Healthy Adults

Interventions

BIOLOGICAL

Vaccine Candidate #1

Investigational influenza Vaccine

BIOLOGICAL

Vaccine Candidate #2

Investigational influenza Vaccine

BIOLOGICAL

Vaccine Candidate #3

Investigational Influenza Vaccine

BIOLOGICAL

Vaccine Candidate #4

Investigational Influenza Vaccine

BIOLOGICAL

Vaccine Candidate #5

Investigational Influenza Vaccine

BIOLOGICAL

Vaccine Candidate #6

Investigational Influenza Vaccine

BIOLOGICAL

TIV1 or TIV2

Licensed influenza vaccine

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-23
Primary Completion
2027-06-22
Completion
2027-06-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07431853 on ClinicalTrials.gov